Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Phase 3positiveVanrafiaPositive
AI Analysis
Summary
Novartis announced final 2.5-year Phase III ALIGN data showing Vanrafia (atrasentan) significantly slowed kidney function decline in IgA nephropathy patients compared to placebo, with sustained proteinuria reduction published in The Lancet.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Final 2.5-year ALIGN Phase III results showed clinically meaningful slowing of kidney function decline with Vanrafia versus placebo, with sustained proteinuria reduction and benefits consistent across patient subgroups including those on SGLT2 inhibitors
Importance:8/10
Sentiment:
0.85
Phase IIIkidney diseaseendothelin receptor antagonistproteinuriaefficacyThe Lancet
Related Companies
Read the original article
Published by GlobeNewswire Pharma on June 4, 2026 10:15 AM